 Liminal BioSciences is an innovative biopharmaceutical company with a broad pipeline of small molecule therapeutics under development to address unmet needs in patients with liver, respiratory and kidney disease, with a focus on rare and orphan diseases. Liminal BioSciences research involves the study of several G-protein-coupled-receptors, known as free fatty acid receptors FFARs. 